SCI论文：

1. Li J, Wang SY, Yan KX, Wang P, Jiao J, Wang YD, Chen ML, Dong Y*, Zhong JC*. Intestinal microbiota by angiotensin receptor blocker therapy exerts protective effects against hypertensive damages. IMeta, 2024; 3(4):e222. DOI: 10.1002/imt2.222  (共同通讯作者;SCI IF=33.2；JCR Q1)

2. Chen Y, Chen Z, Liang L, Li J, Meng L, Yuan W, Xie B, Zhang X, Feng L, Jia Y, Fu Z, Su P, Tong Z*, Zhong J*, Liu X*. Multi-kingdom gut microbiota dysbiosis is associated with the development of pulmonary arterial hypertension. EBioMedicine. 2025 May; 115:105686. （共同通讯作者；SCI IF=10.8；JCR Q1)

3. Chen YF, Qi RQ, Song JW, Wang SY, Dong ZJ, Chen YH, Liu Y, Zhou XY, Li J, Liu XY, Zhong JC*. Sirtuin 7 ameliorates cuproptosis, myocardial remodeling and heart dysfunction in hypertension through the modulation of YAP/ATP7A signaling. Apoptosis, 2024;29(11-12):2161-2182. (通讯作者; IF=8.1；JCR Q1)

4. Li XT, Song JW, Zhang ZZ, Zhang MW, Liang LR, Miao R, Liu Y, Chen YH, Liu XY, Zhong JC*. Sirtuin mitigates renal ferroptosis, fibrosis and injury in hypertensive mice by facilitating the KLF15/Nrf2 signaling. Free Radic Biol Med. 2022 Nov 20;193(Pt 1):459-473.  (通讯作者；SCI IF=8.2；JCR Q1）

5. Zhang Z, Tang J, Song J, Xie M, Liu Y, Dong Z, Liu X, Li X, Zhang M, Chen Y, Shi H*, Zhong J*. Elabela alleviates ferroptosis, myocardial remodeling, fibrosis and heart dysfunction in hypertensive mice by modulating the IL-6/STAT3/GPX4 signaling. Free Radic Biol Med. 2022 Feb 2:181(1): 130-142. (共同通讯作者；SCI IF=8.2；JCR Q1）

6. An K, Jia Y, Xie B, Jie Gao, Chen Y, Yuan W, Zhong J*, Su P*, Liu X*. Alterations in the gut mycobiome with coronary artery disease severity. EBioMedicine. 2024; 103:105137. (共同通讯作者;SCI IF=11.1; JCR Q1)

7. Miao R, Dong X, Gong J, Wang Y, Guo X, Li Y, Li J, Yang S, Kuang T, Wan J, Liu M, Zhai Z, Zhong J*,Yang Y*. Possible immune regulation mechanisms for the progression of chronic thromboembolic pulmonary hypertension. Thromb Res. 2021;198:122-131. （共同通讯作者；SCI IF=10.4; JCR Q1)

8. Li X, Liu Y, Song J, Zhong J*. Increased plasma ACE2 concentration does not mean increased risk of SARS-CoV-2 infection and increased fatality rate of COVID-19. Acta Pharm Sin B. 2020 Oct;10(10):2010-2014. （通讯作者；SCI IF= 14.5；JCR Q1） 

9.Zuo K, Li J, Li K, Hu C, Gao Y, Chen M, Hu R, Liu Y, Chi H, Wang H, Qin Y, Liu X, Li S, Cai J, Zhong J*, Yang X*. Disordered gut microbiota and alterations in metabolic patterns are associated with atrial fibrillation. Gigascience. 2019; 8(6):giz058. （共同通讯作者；SCI IF=11.8；JCR Q1)

10. Qi RQ, Chen YF, Cheng J, Song JW, Chen YH, Wang SY, Liu Y, Yan KX, Liu XY, Li J, Zhong JC*. Elabela alleviates cuproptosis and vascular calcification in vitaminD3- overloaded mice via regulation of the PPAR-γ /FDX1 signaling. Mol Med. 2024 Nov 20; 30(1):223.  (通讯作者; IF=6.4；JCR Q1) 

11. Wang S, Yan K, Dong Y, Chen Y, Song J, Chen Y, Liu X, Qi R, Zhou X, Zhong J*, Li J*. The influence of microplastics on hypertension-associated cardiovascular injury via the modulation of gut microbiota. Environ Pollut. 2025 Mar 1;368:125760. （共同通讯作者；SCI IF=7.6；JCR Q1)

12. Chen YF, Qi RQ, Zhao L, Liang LR, Song JW, Zhou XY, Chen YH, Wang SY, Wang Q, Liu Y, Dong Y, Liu XY, Li J, Zhong JC*. Aprocitentan mitigates doxorubicin-induced cardiotoxicity by inhibiting cuproptosis, oxidative stress, and mitochondrial impairments via the activation of sirtuin 7. Int Immunopharmacol. 2025 Feb 20;148:114141. （通讯作者；SCI IF=4.8；JCR Q1)

13. Chen YF, Li XT, Wang SY, Miao R*, Zhong JC*. Targeting Iron Metabolism and Ferroptosis as Novel Therapeutic Approaches in Cardiovascular Diseases. Nutrients 2023, 15, 591. （共同通讯作者；SCI IF=6.7 JCR Q1）

14. Chen YH, Yuan W, Meng LK, Zhong JC*, Liu XY*. The Role and Mechanism of Gut Microbiota in Pulmonary Arterial Hypertension. Nutrients. 2022, 14, 4278. https://doi.org/10.3390/nu14204278  （共同通讯作者；SCI IF=6.7 JCR Q1）

15. Li XT, Zhang YP, Zhang MW, Zhang ZZ, Zhong JC*. Sirtuin 7 serves as a promising therapeutic target for cardiorenal diseases. Eur J Pharmacol. 2022 May 2;925:174977. doi: 10.1016/j.ejphar.2022.174977.  (通讯作者；SCI IF=5.1 JCR Q1）

16. Fang C, Zuo K, Fu Y, Zhu X, Li J, Zhong J*, Xu L*, Yang X*. Aggravated Gut Microbiota and Metabolomic Imbalances Are Associated with Hypertension Patients Comorbid with Atrial Fibrillation. Biomolecules. 2022 Oct 9;12(10):1445. doi: 10.3390/biom12101445. （共同通讯作者；SCI IF=5.5 JCR Q1）

17.Song JW, Tang JQ, Zhang ZZ, Liu Y, Zhong JC*.Targeting the elabela/apelin-apelin receptor axis as a novel therapeutic approach for hypertension.Chin Med J (Engl). 2022. 135(9):1019-1026.  (通讯作者；SCI IF=7.3; JCR Q1)

18. Meng L, Yuan W, Chi H, Han R, Zhang Y, Pan X, Meng J, Liu Y, Song J, Zhong J*, Liu X*. Genetic deletion of CMG2 exacerbates systemic-to-pulmonary shunt-induced pulmonary arterial hypertension. FASEB J. 2021 Apr;35(4):e21421. (共同通讯作者；SCI IF=5.8  JCR Q1)

19. Wang J, Wei L, Yang X*,Zhong J*. Roles of growth differentiation factor 15 in atherosclerosis and coronary artery disease. J Am Heart Assoc. 2019;8(17):e012826. doi: 10.1161/JAHA.119.012826. （共同通讯作者；SCI IF=6.1 JCR Q1)

20. Zheng ML, Liu XY, Han RJ, Yuan W, Sun K, Zhong JC*, Yang XC*. Circulating exosomal long non-coding RNAs in patients with acute myocardial infarction. J Cell Mol Med. 2020 Aug;24(16):9388-9396.  （共同通讯作者；SCI IF=5.3; JCR Q1)

21. Song J, Chen Y, Chen Y, Wang S, Dong Z, Liu X, Li X, Zhang Z, Sun L*, Zhong J*. Ferrostatin-1 Blunts Right Ventricular Hypertrophy and Dysfunction in Pulmonary Arterial Hypertension by Suppressing the HMOX1/GSH Signaling. J Cardiovasc Transl Res. 2024 Feb;17(1):183-196..  (共同通讯作者；SCI IF=3.4 JCR Q2）

22. Song JJ, Yang M, Liu Y, Song JW, Wang J, Chi HJ, Liu XY, Zuo K, Yang XC,Zhong JC*. MicroRNA-122 aggravates angiotensin II-mediated apoptosis and autophagy imbalance in rat aortic adventitial fibroblasts via the modulation of SIRT6-elabela-ACE2 signaling. Eur J Pharmacol. 2020 Sep 15;883:173374. doi: 10.1016/j.ejphar.2020.173374.  （通讯作者；SCI IF=5.0; JCR Q1)

23. Miao R, Gong J, Zhang C, Wang Y, Guo X, Li J, Yang S, Kuang T, Zhong J*, Feng H*. Hsa_circ_0046159 is involved in the development of chronic thromboembolic pulmonary hypertension. J Thromb Thrombolysis. 2020; 49(3):386-394. （共同通讯作者；SCI IF=5.2; JCRQ2)

24.Song J, Zhang Z, Dong Z, Liu X, Liu Y, Li X, Xu Y, Guo Y, Wang N, Zhang M, Chen Y, Jin H*, Zhong J*. MicroRNA-122-5p Aggravates Angiotensin II-Mediated Myocardial Fibrosis and Dysfunction in Hypertensive Rats by Regulating the Elabela/Apelin-APJ and ACE2-GDF15-Porimin Signaling. J Cardiovasc Transl Res. 2022;15(3):535-547. (共同通讯作者；SCI IF=4.1; JCR Q2)

25. Qi RQ, Chen YF, Yang XY, Dong ZJ, Zhao L, Li WM, Cheng J, Wang Q, Li J, Zhong JC*.  The antihypertensive agent ACT-132577 alleviates cuproptosis and pressure-overload-induced vascular remodelling by modulation of the NEDD4-LCTR1-copper signaling.FEBS J. 2025 Nov 28. doi: 10.1111/febs.70341. （SCI IF=5.5； JCR Q1)

26. Li XT, Zhang MW, Zhang ZZ, Cao YD, Liu XY, Miao R, Xu Y, Song XF, Song JW, Liu Y, Xu YL, Li J, Dong Y, Zhong JC*. Abnormal apelin-ACE2 and SGLT2 signaling contribute to adverse cardiorenal injury in patients with COVID-19. Int J Cardiol. 2021; 336(1): 123-129. 2021.05.029. (通讯作者；SCI IF= 4.1； JCR Q2)

27. Ma Z, Song JJ, Martin S, Yang XC*, Zhong JC*. The Elabela-APJ axis: a promising therapeutic target for heart failure. Heart Fail Rev. 2021; 26(5):1249-1258. （共同通讯作者；SCI IF=4.6 JCR Q1) 

28. Zhong JC#, Zhang ZZ#, Wang W, McKinnie SM, Vederas JC, Oudit GY*. Targeting the apelin pathway as a novel therapeutic approach for cardiovascular diseases. Biochim Biophys Acta-Mol Bas Dis. 2017; 1863(8):1942-1950. (第一作者；SCI, IF=6.6； JCR Q1）

29.Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, Raizada MK, Grant MB, Oudit GY*. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020 May 8; 126(10):1456-1474. (SCI IF=23.2; JCR Q1)

30. Zhou X, Li J, Guo J, Geng B, Ji W, Zhao Q, Li J, Liu X, Liu J, Guo Z, Cai W, Ma Y, Ren D, Miao J, Chen S, Zhang Z, Chen J, Zhong J, Liu W, Zou M, Li Y, Cai J. Gut-dependent microbial translocation induces inflammation and cardiovascular events after ST-elevation myocardial infarction. Microbiome. 2018 Apr 3;6(1):66. doi: 10.1186/s40168-018-0441-4. (SCI IF=16.8 JCR Q1)

31. Zhang ZZ, Wang W, Jin HY, Chen X, Cheng YW, Xu YL, Song B, Penninger JM, Oudit GY*, Zhong JC*. Pyr-apelin-13 is a negative regulator of angiotensin II-mediated adverse myocardial remodeling and dysfunction. Hypertension. 2017; 70(6):1165-1175.（通讯作者；SCI, IF=10.1；JCR Q1）

32.Zhang MW, Li XT, Zhang ZZ, Liu Y, Song JW, Liu XM, Chen YH, Wang N, Guo Y, Liang LR*, Zhong JC*. Elabela blunts doxorubicin-induced oxidative stress and ferroptosis in rat aortic adventitial fibroblasts by activating the KLF15/GPX4 signaling. Cell Stress Chaperones. 2023;28(1):91-103；DOI : 10.1007/s12192-022-01317-6. (共同通讯作者；SCI IF=3.8 JCR Q3)

33. Song JJ, Yang M, Liu Y, Song JW, Liu XY, Miao R, Zhang ZZ, Liu Y, Fan YF, Zhang Q, Dong Y, Yang XC, Zhong JC*. Elabela prevents angiotensin II-induced apoptosis and inflammation in rat aortic adventitial fibroblasts via the activation of FGF21-ACE2 signaling. J Mol Histol. 2021；52(5):905-918. doi: 10.1007/s10735-021-10011-3. （通讯作者；SCI IF=3.2 JCR Q3）

34. Song J, Chen Y, Chen Y, Wang S, Dong Z, Liu X, Li X, Zhang Z, Sun L*, Zhong J*. Ferrostatin-1 Blunts Right Ventricular Hypertrophy and Dysfunction in Pulmonary Arterial Hypertension by Suppressing the HMOX1/GSH Signaling. J Cardiovasc Transl Res. 2024. 17(1):183-196. doi: 10.1007/s12265-023-10423-4.   (共同通讯作者；SCI IF=3.4 JCR Q2）

35. Wang J, Wang J, Zhong J, Liu H, Li W, Chen M, Xu L, Zhang W, Zhang Z, Wei Z, Guo J, Wang X, Sui J, Liu X, Zhang S, Wang X. LRG1 promotes atherosclerosis by inducing macrophage M1-like polarization. Proc Natl Acad Sci U S A 2024；121(35):e2405845121. （共同作者；SCI IF=9.7 JCR Q1）

36.Zhong JC, Guo D, Chen CB, Wang W, Shuster M, Loibner H, Penninger JM, Scholey JW, Kassiri Z, Oudit GY. Prevention of angiotensin II-mediated renal oxidative stress, inflammation and fibrosis by angiotensin converting enzyme 2. Hypertension. 2011; 57(2):314-322.(第一作者；SCI IF=10.1  JCR Q1)

37. Zhong JC, Basu R, Guo D, Chow FL, Byrns S, Shuster M, Loibner H, Wang X, Penninger JM, Kassiri Z, Oudit GY*. Angiotensin converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis and cardiac dysfunction. Circulation. 2010; 122:717-728.(第一作者；SCI IF=38.7  JCR Q1)

38. Jin HY, Chen LJ, Zhang ZZ, Xu YL, Song B, Xu R, Oudit GY, Gao PJ, Zhu DL,Zhong JC*. Deletion of angiotensin-converting enzyme 2 exacerbates renal inflammation and injury in apolipoprotein E-deficient mice through modulation of the nephrin and TNF-alpha-TNFRSF1A signaling.J Transl Med. 2015 Aug 6  (通讯作者；SCI IF=7.5  JCR Q1)

39.Zhang Z, Chen L,Zhong J*, Gao P, Oudit GY.  ACE2/Ang-(1-7) signaling and vascular remodeling. Sci China Life Sci.2014 Aug

 (通讯作者；SCI IF=9.5  JCR Q1)

40. Zhang ZZ, Shang QH, Jin HY, Song B, Oudit GY, Lu L, Zhou T, Xu YL, Gao PJ, Zhu DL, Penninger JM,Zhong JC*.Cardiac protective effects of irbesartan via the PPAR-gamma signaling pathway in angiotensin-converting enzyme 2-deficient mice. J Transl Med.2013; (通讯作者；SCI IF=7.5  JCR Q1)

 41. Zhou X, Liu Y, Guo Y, Wang N, Wang S, Song J, Dong Z, Yang X, Chen Y, Li J, Zhao L, Dong Y, Zhong J*. Plasma SIRT7 as a novel biomarker for coronary artery disease and rehospitalization risk in hypertensive patients: a cross-sectional and longitudinal study.Intern Emerg Med. 2025 Aug 30. DOI: 10.1007/s11739-025-04092-1 (共同通讯作者；SCI IF=3.8  JCR Q1)

42. Chen Y, Meng L, Yuan W, Gao Z, Zhang X, Xie B, Song J, Li J, Zhong J*, Liu X*. Gut Fungal Microbiota Alterations in Pulmonary Arterial Hypertensive Rats. Biomedicines. 2024 Jan 27;12(2):298. doi: 10.3390/biomedicines12020298.(共同通讯作者；SCI IF=4.7  JCR Q1)

43. Wang J*, Wu Q, Wang X, Liu H, Chen M, Xu L, Zhang Z, Li K, Li W*, Zhong J*. Targeting Macrophage Phenotypes and Metabolism as Novel Therapeutic Approaches in Atherosclerosis and Related Cardiovascular Diseases.Curr Atheroscler Rep. 2024 Aug 12.26(10):573-588 doi: 10.1007/s11883-024-01229-z. (共同通讯作者;SCI IF=5.7; JCR Q1)

专著：

1.《实用高血压学》第4版（上、下卷）；主编；科学出版社，202306；字数:3084000；中国版本图书馆CIP数据核字（2022）第232715号；ISBN 9787030741301。

2. 《继发性与难治性高血压》；编委，人民卫生出版社，202305；字数438000；中国版本图书馆CIP数据核字（2023）第076997号；ISBN 9787117347617

3. 《高血压规范化防治－从指南到实践》；编委，北京大学医学出版社；201712;

4. 《高血压病学--从基础到临床，从指南到实践》；编委，科学出版社。201911；中国版本图书馆CIP数据核字（2019）第245339号；ISBN9787030630070

5. 《高血压学》；编委，科学出版社。201909；中国版本图书馆CIP数据核字（2019）第166835号；ISBN978-7-03-062037-8

6. 《心血管内科实践》，编委，科学出版社，202108；中国版本图书馆CIP数据核字（2022）第101125号；ISBN978-7-03-072506-6

7. 《高血压与糖尿病防治新策略》，编委，上海科学技术出版社，202108，中国版本图书馆CIP数据核字（2021）第126618号；ISBN978754785391/R*2324

8. 《中国老年高血压管理指南（2023）》，编委，人民卫生出版社，北京，202306，中国版本图书馆CIP数据核字（2023）第109160号；ISBN978-7-117-35002-0

9. 血管医学教科书Textbook of Vascular Medicine 编委，中华医学电子音像出版社. 2025年6月18日；ISBN 9787830054885

科技获奖:

1.2024年度首都医科大学科科学技术奖自然科学奖二等奖；获奖项目名称：高血压心肾损伤新机制；署名顺序：钟久昌、赵林、李晶、缪冉、刘晓艳、李惟铭、董莹、宋佳玮；

2. 高血压心血管重构损伤的作用机制研究；首都医科大学2021年度科技奖励自然科学奖，三等奖；署名顺序：钟久昌、杨新春、张振洲、缪冉、刘颖、李雪婷、马铮、宋娟娟

3.外泌体携带lncRNA在冠心病所致心衰中的研究；首都医科大学2020年度科技奖励自然科学奖，三等奖；署名顺序：杨新春、郑美丽、钟久昌、陈牧雷、孙昊、刘晔。

4. 2022年首都医科大学科学技术奖励自然科学奖三等奖；获奖项目名称：慢性血栓栓塞性肺动脉高压血管重塑的作用机制研究；署名顺序：杨媛华，缪冉，龚娟妮，杨苏乔，钟久昌，李一丹，郭晓娟，王剑锋

5. 2023年首都医科大学科学技术奖励自然科学奖三等奖；高血压及相关疾病中肠道菌群与代谢物的作用研究；署名顺序：李晶，董莹，钟久昌，等。

发明专利：

1. 2024年国家发明专利：授权日期：2024年8月23日；专利授权号：ZL 2022 1 1384938.9 ; 公开号：CN 115779086 B；专利权人：首都医科大学附属北京朝阳医院；专利名称：SIRT7基因在肺动脉高压中的应用。署名顺序：钟久昌,宋佳玮,缪冉,梁立荣,李雪婷,张振洲,刘晓艳,刘昕明,杨媛华,池洪杰,陈宇飞,陈艺航

2.2024年国家发明专利：授权日期：2024年5月24日；专利授权号：ZL202311319058.8; 公开号：CN117385066B；专利权人：首都医科大学附属北京朝阳医院；专利名称：一种高血压诊断标志物及其应用；署名顺序：董莹，李晶，王攀，陈牧雷，钟久昌，焦洁

3. 2023年国家发明专利：授权日期：2023年6月6日；专利授权号：ZL202211436474.1; 公开号：CN115691790B；专利权人：首都医科大学附属北京朝阳医院；专利名称：一种高血压相关标志物及其应用；署名顺序：李晶，董莹，王攀，陈牧雷，钟久昌，焦洁。

 4. 2022年国家发明专利：授权日期：2022年8月2日；专利授权号ZL202210027558.3；公开日期：2022年03月04；公开号：CN114134226 B 申请日期：2022-01-11；专利权人：首都医科大学附属北京朝阳医院；专利名称：心绞痛相关的标志物及其应用；署名顺序：刘晓艳、刘昕明、王乐丰、陈牧雷、袁雯、谢博洽、钟久昌、陈艺航、安坤、张叶萍

5. 2020年国家发明专利：授权日期：2020年12月29日；专利授权号ZL202010517771.3；公开日期：2020-09-04；公开号：CN111621466 B 申请日期：2020-06-09；专利权人：首都医科大学附属北京朝阳医院；专利名称：一种肺动脉组织单细胞悬液的制备方法及应用；署名顺序：缪冉、杨媛华、钟久昌、翟振国、董星琲、龚娟妮、李一丹、王剑锋、万钧、郭晓娟、王莹、杨苏乔、李积凤、邝土光